Hologic, Inc. $HOLX Shares Sold by Blair William & Co. IL

Blair William & Co. IL decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,560 shares of the medical equipment provider’s stock after selling 16,259 shares during the quarter. Blair William & Co. IL’s holdings in Hologic were worth $3,620,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Chung Wu Investment Group LLC acquired a new stake in shares of Hologic in the second quarter valued at $26,000. Zions Bancorporation National Association UT acquired a new stake in shares of Hologic in the first quarter valued at $34,000. Cromwell Holdings LLC grew its stake in shares of Hologic by 307.0% in the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 436 shares in the last quarter. Allworth Financial LP grew its stake in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 216 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Hologic in the first quarter valued at $42,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HOLX. UBS Group lifted their price objective on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, July 31st. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Argus boosted their target price on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. Mizuho set a $75.00 target price on Hologic in a research note on Thursday, July 31st. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Hologic in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.15.

Hologic Stock Down 3.3%

Shares of NASDAQ HOLX opened at $65.51 on Tuesday. The company has a market capitalization of $14.57 billion, a price-to-earnings ratio of 27.18, a price-to-earnings-growth ratio of 2.32 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The business has a 50-day moving average of $67.10 and a two-hundred day moving average of $63.36. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.88% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.